Phase 1 Study and Dose Seeking Study of an Intravenous Formulation of the Anthracycline Analog GPX-150 in Patients With Solid Tumors

Trial Profile

Phase 1 Study and Dose Seeking Study of an Intravenous Formulation of the Anthracycline Analog GPX-150 in Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2015

At a glance

  • Drugs GPX 150 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Gem Pharmaceuticals
  • Most Recent Events

    • 12 Feb 2015 Results published in the Investigational New Drugs.
    • 04 Aug 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Additional lead center and company (Gem Pharmaceuticals) added as associations field.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top